About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
Not Voodoo

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
Realizations in Biostatistics
ChemSpider Blog
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Eye on FDA
Chemical Forums
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa

Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
Gene Expression (I)
Gene Expression (II)
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net

Medical Blogs
DB's Medical Rants
Science-Based Medicine
Respectful Insolence
Diabetes Mine

Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem

Politics / Current Events
Virginia Postrel
Belmont Club
Mickey Kaus

Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« Silver Tongues, Golden Hands? | Main | Am I Blue? »

October 2, 2002

Voluntary. . .For Now

Email This Entry

Posted by Derek

HHS has fired a warning shot across the bow of the drug industry. These draft guidelines don't have the force of law behind them (yet,) but the implication seems clear: shape up, or they will.

This election cycle has seen some grandstanding against the drug companies (and without foreign policy intruding, there would surely have been more.) The industry has to realize that the political wind is against it these days. Nobody's in the mood to hear some more stories about a powerful industry throwing money around to influence people.

I feel a bit odd saying this, but I wouldn't mind seeing some of the restrictions made mandatory, with some vigorous enforcement. It would defuse the marketing arms race in the industry a bit, and it's for sure that nothing else will. Companies will, of course, act in their own interests - it's silly to expect them not to. And as things are set up, it's in their interest to market as aggressively as possible. There aren't that many wonderful new drugs to sell these days, which puts increasing pressure on both the existing portfolio and on anything new that might come up.

I can go on like this because marketing types and drug-discovery types don't spend much time interacting, and tend to regard each other as alien beings. To us, although we realize the value of advertising, some of the marketing campaigns seem in danger of tipping the balance to where they start to eat into the potential profits of the drugs - a diminishing-returns situation. To them, research seems like the black-hole cost center that untold zillions of dollars go spiraling into - and for what? Where's something that they can sell?

Maybe some of the blogger physicians (you, and you, and you, for starters!) can report over the next few weeks or months if they're noticing anything different.

Comments (0) + TrackBacks (0) | Category: Why Everyone Loves Us



Email this entry to:

Your email address:

Message (optional):

The Last Post
The GSK Layoffs Continue, By Proxy
The Move is Nigh
Another Alzheimer's IPO
Cutbacks at C&E News
Sanofi Pays to Get Back Into Oncology
An Irresponsible Statement About Curing Cancer
Oliver Sacks on Turning Back to Chemistry